Quick Answer
Whitehawk Therapeutics, Inc. reported Total Revenue of $7.14 million for fiscal year 2025.
Whitehawk Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $7.14M -72.5% |
$25.98M +6.7% |
$24.35M +60.1% |
$15.22M +8.7% |
$14.00M +0.0% |
$14.00M |
| Revenue (ASC 606) | $7.14M -72.5% |
$25.98M +6.7% |
$24.35M +60.1% |
$15.22M +8.7% |
$14.00M +0.0% |
$14.00M |
| Net Income | -$20.60M +67.7% |
-$63.69M +3.2% |
-$65.77M -8.7% |
-$60.51M +45.0% |
-$110.09M -3065.3% |
-$3.48M +85.1% |
| Diluted EPS | -$0.33 +86.0% |
-$2.36 +3.3% |
-$2.44 +9.3% |
-$2.69 +78.3% |
-$12.41 | — |
| Total Assets | $150.83M +114.5% |
$70.32M -46.9% |
$132.42M -28.1% |
$184.24M +16.7% |
$157.91M +738.8% |
$18.82M -52.9% |
| Cash and Equivalents | $37.57M +31.0% |
$28.67M -54.4% |
$62.89M +61.2% |
$39.02M -73.8% |
$148.99M +3244.3% |
$4.46M -88.4% |
| Stockholders Equity | $136.31M +159.7% |
$52.48M -50.1% |
$105.19M -33.6% |
$158.38M +16.1% |
$136.41M +1197.2% |
-$12.43M -36.7% |
| R&D Expense | $90.96M +78.3% |
$51.03M +4.3% |
$48.93M +49.8% |
$32.66M +66.0% |
$19.67M +31.1% |
$15.01M +17.0% |
| Operating Income | -$114.40M -69.6% |
-$67.46M +6.2% |
-$71.93M -14.8% |
-$62.68M +43.6% |
-$111.22M -4263.2% |
-$2.55M +89.6% |
| Shares Outstanding | 47.15M +91.0% |
24.68M +0.5% |
24.55M +0.5% |
24.44M +877.4% |
2.50M -1.7% |
2.54M -93.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | -100.0% | — |
| Net Income | September 30, 2025 | -$17.75M | -41.4% | +66.3% |
| Diluted EPS | September 30, 2025 | -$0.26 | +43.5% | +65.8% |
| Total Assets | September 30, 2025 | $167.02M | +94.9% | -7.6% |
| Cash and Equivalents | September 30, 2025 | $37.93M | +24.2% | -73.8% |
| Stockholders Equity | September 30, 2025 | $157.17M | +128.2% | -8.7% |
| R&D Expense | September 30, 2025 | $14.35M | +43.5% | -70.6% |
| Operating Income | September 30, 2025 | -$19.55M | -45.7% | +64.3% |
| Shares Outstanding | September 30, 2025 | 47.13M | +91.5% | +0.0% |
- Whitehawk Therapeutics, Inc. reported Total Revenue of $7.14 million for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed a decrease of -72.5% in Total Revenue compared to the prior fiscal year.
- Whitehawk Therapeutics, Inc. reported Revenue (ASC 606) of $7.14 million for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed a decrease of -72.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Whitehawk Therapeutics, Inc. reported Net Income of -$20.60 million for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed an increase of +67.7% in Net Income compared to the prior fiscal year.
- Whitehawk Therapeutics, Inc. reported Diluted EPS of $0.33 per share (loss) for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed an increase of +86.0% in Diluted EPS compared to the prior fiscal year.
- Whitehawk Therapeutics, Inc. reported Total Assets of $150.83 million for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed an increase of +114.5% in Total Assets compared to the prior fiscal year.
- Whitehawk Therapeutics, Inc. reported Cash and Equivalents of $37.57 million for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed an increase of +31.0% in Cash and Equivalents compared to the prior fiscal year.
- Whitehawk Therapeutics, Inc. reported Stockholders Equity of $136.31 million for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed an increase of +159.7% in Stockholders Equity compared to the prior fiscal year.
- Whitehawk Therapeutics, Inc. reported R&D Expense of $90.96 million for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed an increase of +78.3% in R&D Expense compared to the prior fiscal year.
- Whitehawk Therapeutics, Inc. reported Operating Income of -$114.40 million for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed a decrease of -69.6% in Operating Income compared to the prior fiscal year.
- Whitehawk Therapeutics, Inc. reported Shares Outstanding of 47.15 million shares for fiscal year 2025.
- Whitehawk Therapeutics, Inc. showed an increase of +91.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: